These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 11304935

  • 1. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
    Aoki T, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y.
    Arzneimittelforschung; 2001; 51(3):197-203. PubMed ID: 11304935
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K, Pineda G, Newton RS, Fernandez ML.
    Biochem Pharmacol; 1999 Oct 01; 58(7):1209-19. PubMed ID: 10484079
    [Abstract] [Full Text] [Related]

  • 4. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits.
    Suzuki H, Yamazaki H, Aoki T, Kojima J, Tamaki T, Sato F, Kitahara M, Saito Y.
    Arzneimittelforschung; 2000 Nov 01; 50(11):995-1003. PubMed ID: 11187394
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y.
    Arzneimittelforschung; 1997 Aug 01; 47(8):904-9. PubMed ID: 9296275
    [Abstract] [Full Text] [Related]

  • 6. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov 01; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 8. Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
    Amano Y, Ishikawa E, Shinozawa E, Shimada M, Miura S, Adachi R, Tozawa R.
    Life Sci; 2014 Jul 11; 108(1):7-12. PubMed ID: 24805868
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 11; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 11. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 12. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 10; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 13. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
    Uyuklu M, Meiselman HJ, Baskurt OK.
    Clin Hemorheol Microcirc; 2007 May 10; 36(1):25-33. PubMed ID: 17211059
    [Abstract] [Full Text] [Related]

  • 14. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.
    Conde K, Vergara-Jimenez M, Krause BR, Newton RS, Fernandez ML.
    J Lipid Res; 1996 Nov 10; 37(11):2372-82. PubMed ID: 8978489
    [Abstract] [Full Text] [Related]

  • 15. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR, Newton RS.
    Atherosclerosis; 1995 Oct 10; 117(2):237-44. PubMed ID: 8801869
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
    Liu CS, Lii CK, Chang LL, Kuo CL, Cheng WL, Su SL, Tsai CW, Chen HW.
    Nutr Res; 2010 Feb 10; 30(2):118-24. PubMed ID: 20226997
    [Abstract] [Full Text] [Related]

  • 17. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J.
    Can J Cardiol; 1998 May 10; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [Abstract] [Full Text] [Related]

  • 18. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
    Schrott HG, Knapp H, Davila M, Shurzinske L, Black D.
    Am Heart J; 2000 Aug 10; 140(2):249-52. PubMed ID: 10925339
    [Abstract] [Full Text] [Related]

  • 19. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 10; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 20. Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
    Gianturco SH, Gotto AM, Jackson RL, Patsch JR, Sybers HD, Taunton OD, Yeshurun DL, Smith LC.
    J Clin Invest; 1978 Feb 10; 61(2):320-8. PubMed ID: 202612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.